NA-931 (Bioglutide, 10mg)

Buy NA-931 (Bioglutide, 10mg) Online | BehemothLabz

NA-931 is a synthetic investigational small molecule compound. Researchers also refer to it as Bioglutide. It is derived from a metabolite of insulin-like growth factor 1 (IGF-1) and is classified as the first-in-class oral quadruple receptor agonist designed to simultaneously engage four receptor systems involved in metabolic regulation: the IGF-1 receptor (IGF-1R), the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This quadruple receptor profile was confirmed in the ADA 2025 Phase 2 clinical abstract, representing an expanded characterization from the triple agonist (IGF-1R/GLP-1R/GIPR) profile described in preclinical DIO mouse data presented at ADA 2024.

So, why do researchers find NA-931 useful? Because it provides a single tool for studying the simultaneous activation of four complementary metabolic receptor pathways. Its quadruple receptor engagement profile makes it a distinctive research compound for investigating how concurrent IGF-1R, GLP-1R, GIPR, and GCGR agonism interacts in metabolic signaling studies compared to single, dual, or triple receptor agonist reference compounds. Unlike conventional incretin-based peptides that require parenteral administration, NA-931 is under investigational evaluation for oral bioavailability, with this property proposed to arise from its derivation as a cyclic lipophilic IGF-1 fragment. Oral bioavailability in peptide-based compounds is atypical and remains a specific subject of investigation within the NA-931 research program [Tran, ADA 2025].

ATTENTION: This product is strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use.

Mechanism of Action of NA-931

How Does NA-931 Engage Multiple Metabolic Receptor Systems?

NA-931 is thought to act as a simultaneous agonist at IGF-1R, GLP-1R, GIPR, and GCGR in preclinical experimental systems. Each receptor system contributes distinct pathway inputs in metabolic research models. GLP-1R engagement in pancreatic and hypothalamic cell models is associated with glucose-dependent insulin secretion and appetite-related signaling modulation. GIPR activation in pancreatic and adipose tissue models is linked to complementary insulinotropic effects and lipid metabolism modulation. Glucagon receptor activation in hepatic and adipose cell systems is examined for its role in energy expenditure modulation and hepatic glucose output. IGF-1R engagement is studied for its relationship to lean tissue preservation and insulin sensitivity in metabolic models.

The potential for GLP-1R and GIPR agonists to interact with central nervous system circuits governing appetite, cognition, and energy homeostasis is an active area of investigation across the incretin class. Class-level mechanistic findings on GLP-1-based multi-receptor compounds and their CNS interactions provide a research framework relevant to NA-931’s pathway pharmacology in experimental settings [Son et al., 2026].

Note: Son et al. (2026) is a systematic review of novel GLP-1-based medications that does not specifically name or evaluate NA-931. This reference is cited to establish the class-level mechanistic framework of multi-receptor incretin agonism within which NA-931 is investigated. Findings from this review apply to the broader compound class and should not be interpreted as compound-specific evidence for NA-931.

IGF-1 Metabolite Origin and Oral Administration Profile

NA-931’s structural origin as a cyclic IGF-1 fragment metabolite is proposed to confer oral bioavailability and blood-brain barrier permeability in preclinical and investigational settings, properties atypical for peptide-based compounds. This pharmacokinetic characteristic is a specific subject of investigation and distinguishes NA-931 from standard incretin peptide analogs used as comparators in the same research settings.

Properties of NA-931 (Bioglutide)

Research Findings on NA-931

Preclinical DIO mouse model data presented at the ADA 84th Scientific Sessions examined NA-931 and its analogs NA-932 and NA-933 for their effects on body weight and metabolic parameters. In this preclinical setting, NA-931 was characterized as a triple agonist targeting IGF-1R, GLP-1R, and GIPR. Observed outcomes included dose-dependent reductions in body weight alongside improvements in lipid profile parameters, with no muscle loss or serious adverse effects reported. These findings are from preclinical animal model settings only and data remains limited [Tran, ADA 2024].

Phase 2 clinical investigation of NA-931 as a quadruple IGF-1R/GLP-1R/GIPR/GCGR receptor agonist was presented at the ADA 85th Scientific Sessions in June 2025. The study was a 13-week randomized, double-blind, placebo-controlled parallel arm trial enrolling adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (ClinicalTrials.gov ID NCT06564753). Results demonstrated dose-dependent body weight reductions of up to 14.8% at 150mg daily dosing, representing a 13.2% greater reduction versus placebo. Up to 72% of NA-931-treated subjects achieved ≥12% weight loss compared with 2% in the placebo group. No muscle loss was observed. Treatment-emergent adverse events were predominantly mild. These findings are from human clinical research conducted under IRB-approved protocols. They are cited for clinical development context only and do not apply to the research-grade formulation supplied here. NA-931 has no approved indication [Tran, ADA 2025].

All preclinical studies referenced above were conducted under institutional oversight consistent with IRB, IACUC, and AWA guidelines. Human clinical Phase 2 data is cited for development context only and does not apply to the research-grade formulation supplied here. NA-931 is supplied by BehemothLabz exclusively for use under equivalent institutional research compliance frameworks.

Note: NA-931 is not approved by the FDA for any use. It is intended strictly for laboratory research purposes only and is not for human consumption.

Risk and Handling Information

Risk Tier: MODERATE

NA-931 is a pharmacologically active multi-receptor agonist with concurrent activity across four metabolic receptor systems. Its complete toxicological profile has not been formally established outside controlled investigational settings. The simultaneous engagement of IGF-1R, GLP-1R, GIPR, and GCGR introduces complex multi-pathway pharmacology that must be treated as uncharacterized for uncontrolled research exposures.

Exposure Risk

Lyophilized powder presents an inhalation hazard. All weighing, reconstitution, and handling must be performed inside a certified fume hood or biosafety cabinet. N95 respiratory protection is required during any powder manipulation. Nitrile gloves, a lab coat, and safety eyewear are mandatory during all handling procedures. Direct skin and eye contact must be avoided.

Metabolic Pathway Risk

GLP-1R and GIPR agonism in uncontrolled exposure contexts may present risks related to uncharacterized insulin secretion pathway activation. GCGR agonism carries risks related to hepatic glucose metabolism dysregulation. IGF-1R activity in uncontrolled settings may interact with cell proliferation signaling pathways. Any accidental human exposure must be treated as a potential pharmacological event and managed per institutional first-aid and incident reporting protocols.

Storage Risk

Store lyophilized material at −20°C in sealed vials, protected from light and moisture. Reconstituted solution must be used within 7 days and kept at 4°C. Repeated freeze-thaw cycling must be avoided. Single-use aliquoting before initial reconstitution is strongly recommended.

Disposal

All residual material, vials, syringes, and contaminated consumables must be disposed of in full compliance with applicable institutional biosafety regulations and chemical waste management protocols.

Why Choose BehemothLabz to Buy NA-931?

Researchers choose BehemothLabz for NA-931 based on five verifiable quality markers.

Identity Confirmation: Every batch is verified against the confirmed compound designation NA-931 (Bioglutide) with HPLC retention time analysis. CAS and PubChem CID are not publicly registered for this proprietary investigational compound — identity verification is conducted against the supplied batch COA.

Independent Third-Party Laboratory Testing: Purity analysis is conducted by an independent third-party laboratory. BehemothLabz does not self-certify. HPLC-confirmed purity is ≥99% per batch.

Full Batch Traceability: A Certificate of Analysis is available for every production lot — not a generic representative document.

Phase-Current Research Transparency: NA-931 Phase 2 is complete and Phase 3 is initiating as of June 2026. BehemothLabz product pages reflect current clinical development status so researchers work with up-to-date compound context.

Research-Grade Supply Standards: Supplied as lyophilized powder with ≥24-month shelf life at −20°C, manufactured to rigorous purity standards for qualified researchers in controlled laboratory environments.

Disclaimer

Please make sure you go through the Terms and Conditions and familiarize yourself with them, as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website. All research involving this compound must comply with IRB guidelines for clinical investigations and IACUC directives for animal studies under the Animal Welfare Act (AWA).

Buying the product means you agree to our Terms and Conditions. You can contact our customer service team at support@behemothlabz.com if you are not fully satisfied with the product.

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Reference Links

Tran, L. L. (2024). 2059-LB: NA-931, a novel triple IGF-1/GLP-1/GIP incretin receptor agonist reduces body weight and improves metabolic profile in DIO mice. Diabetes, 73(Supplement 1), 2059-LB. American Diabetes Association 84th Scientific Sessions. https://diabetesjournals.org/diabetes/article/73/Supplement_1/2059-LB/155764/

Tran, L. L. (2025). 2189-LB: Phase 2 clinical trials of NA-931 to study subjects who are obese with at least one weight-related comorbid condition. Diabetes, 74(Supplement 1), 2189-LB. American Diabetes Association 85th Scientific Sessions. https://diabetesjournals.org/diabetes/article/74/Supplement_1/2189-LB/160162/

Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026). Novel GLP-1-based medications for type 2 diabetes and obesity. Endocrine Reviews, 47(2), 159–177. https://pubmed.ncbi.nlm.nih.gov/41054801/